Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines-2016 revision

Jan L Brozek, Jean Bousquet, Ioana O Agache, Arnav Agarwal, Claus Bachert, Sinthia Z Bosnic-Anticevich, Romina Brignardello-Petersen, Giorgio Walter Alter Canonica, Thomas B Casale, Niels H. Chavannes, Jaime Correia de Sousa, Alvaro A. Cruz, Carlos A. Cuello-Garcia, Pascal Demoly, Mark Dykewicz, Itziar Etxeandia-Ikobaltzeta, Ivan D. Florez, Wytske Johanna Fokkens, Joao Almeida Fonseca, Peter W. Hellings & 1 others Robyn O'Hehir

Research output: Contribution to journalArticleOtherpeer-review

227 Citations (Scopus)

Abstract

Background: Allergic rhinitis (AR) affects 10% to 40% of the population. It reduces quality of life and school and work performance and is a frequent reason for office visits in general practice. Medical costs are large, but avoidable costs associated with lost work productivity are even larger than those incurred by asthma. New evidence has accumulated since the last revision of the Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines in 2010, prompting its update. Objective: We sought to provide a targeted update of the ARIA guidelines. Methods: The ARIA guideline panel identified new clinical questions and selected questions requiring an update. We performed systematic reviews of health effects and the evidence about patients' values and preferences and resource requirements (up to June 2016). We followed the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) evidence-to-decision frameworks to develop recommendations. Results: The 2016 revision of the ARIA guidelines provides both updated and new recommendations about the pharmacologic treatment of AR. Specifically, it addresses the relative merits of using oral H1-antihistamines, intranasal H1-antihistamines, intranasal corticosteroids, and leukotriene receptor antagonists either alone or in combination. The ARIA guideline panel provides specific recommendations for the choice of treatment and the rationale for the choice and discusses specific considerations that clinicians and patients might want to review to choose the management most appropriate for an individual patient. Conclusions: Appropriate treatment of AR might improve patients' quality of life and school and work productivity. ARIA recommendations support patients, their caregivers, and health care providers in choosing the optimal treatment.

Original languageEnglish
Pages (from-to)950-958
Number of pages9
JournalJournal of Allergy and Clinical Immunology
Volume140
Issue number4
DOIs
Publication statusPublished - Oct 2017

Keywords

  • Allergic rhinitis
  • Practice guideline

Cite this

Brozek, J. L., Bousquet, J., Agache, I. O., Agarwal, A., Bachert, C., Bosnic-Anticevich, S. Z., ... O'Hehir, R. (2017). Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines-2016 revision. Journal of Allergy and Clinical Immunology, 140(4), 950-958. https://doi.org/10.1016/j.jaci.2017.03.050
Brozek, Jan L ; Bousquet, Jean ; Agache, Ioana O ; Agarwal, Arnav ; Bachert, Claus ; Bosnic-Anticevich, Sinthia Z ; Brignardello-Petersen, Romina ; Canonica, Giorgio Walter Alter ; Casale, Thomas B ; Chavannes, Niels H. ; Correia de Sousa, Jaime ; Cruz, Alvaro A. ; Cuello-Garcia, Carlos A. ; Demoly, Pascal ; Dykewicz, Mark ; Etxeandia-Ikobaltzeta, Itziar ; Florez, Ivan D. ; Fokkens, Wytske Johanna ; Fonseca, Joao Almeida ; Hellings, Peter W. ; O'Hehir, Robyn. / Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines-2016 revision. In: Journal of Allergy and Clinical Immunology. 2017 ; Vol. 140, No. 4. pp. 950-958.
@article{c7334e37ec46466aa8f2606ed0aea2eb,
title = "Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines-2016 revision",
abstract = "Background: Allergic rhinitis (AR) affects 10{\%} to 40{\%} of the population. It reduces quality of life and school and work performance and is a frequent reason for office visits in general practice. Medical costs are large, but avoidable costs associated with lost work productivity are even larger than those incurred by asthma. New evidence has accumulated since the last revision of the Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines in 2010, prompting its update. Objective: We sought to provide a targeted update of the ARIA guidelines. Methods: The ARIA guideline panel identified new clinical questions and selected questions requiring an update. We performed systematic reviews of health effects and the evidence about patients' values and preferences and resource requirements (up to June 2016). We followed the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) evidence-to-decision frameworks to develop recommendations. Results: The 2016 revision of the ARIA guidelines provides both updated and new recommendations about the pharmacologic treatment of AR. Specifically, it addresses the relative merits of using oral H1-antihistamines, intranasal H1-antihistamines, intranasal corticosteroids, and leukotriene receptor antagonists either alone or in combination. The ARIA guideline panel provides specific recommendations for the choice of treatment and the rationale for the choice and discusses specific considerations that clinicians and patients might want to review to choose the management most appropriate for an individual patient. Conclusions: Appropriate treatment of AR might improve patients' quality of life and school and work productivity. ARIA recommendations support patients, their caregivers, and health care providers in choosing the optimal treatment.",
keywords = "Allergic rhinitis, Practice guideline",
author = "Brozek, {Jan L} and Jean Bousquet and Agache, {Ioana O} and Arnav Agarwal and Claus Bachert and Bosnic-Anticevich, {Sinthia Z} and Romina Brignardello-Petersen and Canonica, {Giorgio Walter Alter} and Casale, {Thomas B} and Chavannes, {Niels H.} and {Correia de Sousa}, Jaime and Cruz, {Alvaro A.} and Cuello-Garcia, {Carlos A.} and Pascal Demoly and Mark Dykewicz and Itziar Etxeandia-Ikobaltzeta and Florez, {Ivan D.} and Fokkens, {Wytske Johanna} and Fonseca, {Joao Almeida} and Hellings, {Peter W.} and Robyn O'Hehir",
year = "2017",
month = "10",
doi = "10.1016/j.jaci.2017.03.050",
language = "English",
volume = "140",
pages = "950--958",
journal = "Journal of Allergy and Clinical Immunology",
issn = "0091-6749",
publisher = "Elsevier",
number = "4",

}

Brozek, JL, Bousquet, J, Agache, IO, Agarwal, A, Bachert, C, Bosnic-Anticevich, SZ, Brignardello-Petersen, R, Canonica, GWA, Casale, TB, Chavannes, NH, Correia de Sousa, J, Cruz, AA, Cuello-Garcia, CA, Demoly, P, Dykewicz, M, Etxeandia-Ikobaltzeta, I, Florez, ID, Fokkens, WJ, Fonseca, JA, Hellings, PW & O'Hehir, R 2017, 'Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines-2016 revision', Journal of Allergy and Clinical Immunology, vol. 140, no. 4, pp. 950-958. https://doi.org/10.1016/j.jaci.2017.03.050

Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines-2016 revision. / Brozek, Jan L; Bousquet, Jean; Agache, Ioana O; Agarwal, Arnav; Bachert, Claus; Bosnic-Anticevich, Sinthia Z; Brignardello-Petersen, Romina; Canonica, Giorgio Walter Alter; Casale, Thomas B; Chavannes, Niels H.; Correia de Sousa, Jaime; Cruz, Alvaro A.; Cuello-Garcia, Carlos A.; Demoly, Pascal; Dykewicz, Mark; Etxeandia-Ikobaltzeta, Itziar; Florez, Ivan D.; Fokkens, Wytske Johanna; Fonseca, Joao Almeida; Hellings, Peter W.; O'Hehir, Robyn.

In: Journal of Allergy and Clinical Immunology, Vol. 140, No. 4, 10.2017, p. 950-958.

Research output: Contribution to journalArticleOtherpeer-review

TY - JOUR

T1 - Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines-2016 revision

AU - Brozek, Jan L

AU - Bousquet, Jean

AU - Agache, Ioana O

AU - Agarwal, Arnav

AU - Bachert, Claus

AU - Bosnic-Anticevich, Sinthia Z

AU - Brignardello-Petersen, Romina

AU - Canonica, Giorgio Walter Alter

AU - Casale, Thomas B

AU - Chavannes, Niels H.

AU - Correia de Sousa, Jaime

AU - Cruz, Alvaro A.

AU - Cuello-Garcia, Carlos A.

AU - Demoly, Pascal

AU - Dykewicz, Mark

AU - Etxeandia-Ikobaltzeta, Itziar

AU - Florez, Ivan D.

AU - Fokkens, Wytske Johanna

AU - Fonseca, Joao Almeida

AU - Hellings, Peter W.

AU - O'Hehir, Robyn

PY - 2017/10

Y1 - 2017/10

N2 - Background: Allergic rhinitis (AR) affects 10% to 40% of the population. It reduces quality of life and school and work performance and is a frequent reason for office visits in general practice. Medical costs are large, but avoidable costs associated with lost work productivity are even larger than those incurred by asthma. New evidence has accumulated since the last revision of the Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines in 2010, prompting its update. Objective: We sought to provide a targeted update of the ARIA guidelines. Methods: The ARIA guideline panel identified new clinical questions and selected questions requiring an update. We performed systematic reviews of health effects and the evidence about patients' values and preferences and resource requirements (up to June 2016). We followed the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) evidence-to-decision frameworks to develop recommendations. Results: The 2016 revision of the ARIA guidelines provides both updated and new recommendations about the pharmacologic treatment of AR. Specifically, it addresses the relative merits of using oral H1-antihistamines, intranasal H1-antihistamines, intranasal corticosteroids, and leukotriene receptor antagonists either alone or in combination. The ARIA guideline panel provides specific recommendations for the choice of treatment and the rationale for the choice and discusses specific considerations that clinicians and patients might want to review to choose the management most appropriate for an individual patient. Conclusions: Appropriate treatment of AR might improve patients' quality of life and school and work productivity. ARIA recommendations support patients, their caregivers, and health care providers in choosing the optimal treatment.

AB - Background: Allergic rhinitis (AR) affects 10% to 40% of the population. It reduces quality of life and school and work performance and is a frequent reason for office visits in general practice. Medical costs are large, but avoidable costs associated with lost work productivity are even larger than those incurred by asthma. New evidence has accumulated since the last revision of the Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines in 2010, prompting its update. Objective: We sought to provide a targeted update of the ARIA guidelines. Methods: The ARIA guideline panel identified new clinical questions and selected questions requiring an update. We performed systematic reviews of health effects and the evidence about patients' values and preferences and resource requirements (up to June 2016). We followed the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) evidence-to-decision frameworks to develop recommendations. Results: The 2016 revision of the ARIA guidelines provides both updated and new recommendations about the pharmacologic treatment of AR. Specifically, it addresses the relative merits of using oral H1-antihistamines, intranasal H1-antihistamines, intranasal corticosteroids, and leukotriene receptor antagonists either alone or in combination. The ARIA guideline panel provides specific recommendations for the choice of treatment and the rationale for the choice and discusses specific considerations that clinicians and patients might want to review to choose the management most appropriate for an individual patient. Conclusions: Appropriate treatment of AR might improve patients' quality of life and school and work productivity. ARIA recommendations support patients, their caregivers, and health care providers in choosing the optimal treatment.

KW - Allergic rhinitis

KW - Practice guideline

UR - http://www.scopus.com/inward/record.url?scp=85021395414&partnerID=8YFLogxK

U2 - 10.1016/j.jaci.2017.03.050

DO - 10.1016/j.jaci.2017.03.050

M3 - Article

VL - 140

SP - 950

EP - 958

JO - Journal of Allergy and Clinical Immunology

JF - Journal of Allergy and Clinical Immunology

SN - 0091-6749

IS - 4

ER -

Brozek JL, Bousquet J, Agache IO, Agarwal A, Bachert C, Bosnic-Anticevich SZ et al. Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines-2016 revision. Journal of Allergy and Clinical Immunology. 2017 Oct;140(4):950-958. https://doi.org/10.1016/j.jaci.2017.03.050